dc.contributor.author | Büyük, Başak | |
dc.contributor.author | Aydeğer, Cemre | |
dc.contributor.author | Öztopuz, Özlem | |
dc.contributor.author | Ovalı, Mehmet Akif | |
dc.contributor.author | Makav, Mustafa | |
dc.contributor.author | Eroğlu, Hüseyin Avni | |
dc.date.accessioned | 2023-09-09T11:54:25Z | |
dc.date.available | 2023-09-09T11:54:25Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Büyük, B., Aydeğer, C., Öztopuz, Ö., Ovalı, M. A., Makav, M., & Eroğlu, H. A. (2023). Effects of Ozone Therapy on Chronic Arsenic Poisoning in Rats. Biological Trace Element Research, 201(8), 3951–3960. https://doi.org/10.1007/s12011-022-03486-y | en_US |
dc.identifier.issn | 0163-4984 / 1559-0720 | |
dc.identifier.uri | https://doi.org/10.1007/s12011-022-03486-y | |
dc.identifier.uri | https://hdl.handle.net/20.500.12428/4534 | |
dc.description.abstract | Arsenic (As) is a toxic metalloid that affects many organs through drinking water. This study aims to examine the efficacy of ozone therapy on chronic arsenic toxicity. Twenty-four male Wistar albino rats were housed in individual cages and grouped as control, As, O3, and As + O3. As was applied by adding 5 mg/kg/day in drinking water for 60 days. Ozone therapy was applied at 0.5 mg/kg/day (i.p.) O3 in the last 5 days of the experimental period. Tissues were harvested and analyzed for histopathological injury and apoptotic markers. There was no significant difference between the As + O3 and O3 groups (p = 0.186 and p = 0.599) for light microscopic criteria: inflammatory cell infiltration and hydropic degeneration in liver tissue. In TUNEL assessments, similar outcomes were obtained in the control and As + O3 groups. A statistically significant increase was observed in p53 and Caspase 3 (Casp-3) expression levels in the As group compared to the O3 and As + O3 groups. There was no significant difference between the As + O3 and O3 groups on peritubular hemorrhage and desquamation parameters in kidneys (p = 0.147 and p = 0.094). The KIM-1 expression level was significantly increased in the As group compared to the As + O3 group (p = 0.01), and the Casp-3 expression level was not significantly changed in the O3 group compared to the As + O3 group (p = 0.59). In conclusion, it is determined that ozone therapy has ameliorative effects on the microscopic injury of liver and kidney tissues. In addition to microscopic improvement, KIM-1 gene expression levels were ameliorated in the kidneys. The apoptotic cell counts and the Casp-3 and p53 gene expression levels were decreased by O3 administration. Thus, ozone therapy can be a treatment choice for As toxicity. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Arsenic poisoning | en_US |
dc.subject | Ozone | en_US |
dc.subject | Experimental | en_US |
dc.subject | KIM-1 | en_US |
dc.subject | Liver injury | en_US |
dc.subject | Renal injury | en_US |
dc.title | Effects of Ozone Therapy on Chronic Arsenic Poisoning in Rats | en_US |
dc.type | article | en_US |
dc.authorid | 0000-0003-1654-6406 | en_US |
dc.authorid | 0000-0002-1373-6311 | en_US |
dc.authorid | 0000-0001-8740-6422 | en_US |
dc.authorid | 0000-0002-1040-3255 | en_US |
dc.relation.ispartof | Biological Trace Element Research | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü | en_US |
dc.identifier.volume | 201 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 3951 | en_US |
dc.identifier.endpage | 3960 | en_US |
dc.institutionauthor | Aydeğer, Cemre | |
dc.institutionauthor | Öztopuz, Özlem | |
dc.institutionauthor | Ovalı, Mehmet Akif | |
dc.institutionauthor | Eroğlu, Hüseyin Avni | |
dc.identifier.doi | 10.1007/s12011-022-03486-y | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorwosid | CAH-3653-2022 | en_US |
dc.authorwosid | AFK-7508-2022 | en_US |
dc.authorwosid | - | en_US |
dc.authorwosid | ABF-4291-2021 | en_US |
dc.authorscopusid | 57346882300 | en_US |
dc.authorscopusid | 57194872315 | en_US |
dc.authorscopusid | 55897728300 | en_US |
dc.authorscopusid | 56500220800 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.wos | WOS:000889050000001 | en_US |
dc.identifier.scopus | 2-s2.0-85142729586 | en_US |
dc.identifier.pmid | PMID: 36437433 | en_US |